Interleukin-1 (ɑ&β) Polymorphism and Bevacizumab Response in Neovascular AMD: Jogja Ageing and Genomic AMD Determinant (JAGAD) Study Number 4
Article Sidebar
Main Article Content
Abstract
Introduction: Interleukin-1 (IL-1) gene polymorphisms may influence anti-vascular endothelial growth factor (VEGF) treatment response in neovascular age-related macular degeneration (nAMD) by modulating inflammatory pathways. This study evaluated associations between IL-1 (ɑ&β) and anatomical outcomes following intravitreal bevacizumab.
Methods: We conducted a multi-center retrospective study involving 84 eyes from 71 nAMD patients at three tertiary hospitals in Yogyakarta, Indonesia. Patients were categorized as responders or non-responders according to whether they achieved a >10% reduction in central macular thickness (CMT) one month post-bevacizumab injection. Peripheral blood samples were collected for DNA extraction and genotyping.
Results: Responders demonstrated significantly greater CMT improvement despite having higher baseline values (389.0 µM) compared to non-responders (303.0 µM, p=0.033). At one-month follow-up, responders achieved substantially lower CMT measurements (257.0 µM, p=0.002). The IL-1ɑ risk genotype was not detected in both groups. In addition, the genotype distribution for IL-1ɑ showed no statistical significance difference across age, sex, best corrected visual acuity (BCVA), and CMT. Genetic analysis revealed that carriers of the IL-1β T allele showed a 39% lower probability of being non-responders (OR 0.61; 95% CI 0.32-1.16). The CT and TT genotypes demonstrated even stronger trends, with 34% (OR 0.66; 95% CI 0.15-2.88) and 67% (OR 0.33; 95% CI 0.06-1.72) reduced probabilities of non-response, respectively. However, these associations did not reach statistical significance.
Conclusion: Our findings indicate a potential protective effect of the IL-1β -511C/T polymorphism against poor response to bevacizumab therapy, though statistical significance was not achieved. Further investigation with larger sample sizes is necessary to confirm the predictive value of IL-1 genetic variations for anti-VEGF treatment outcomes in nAMD patients.
Keywords
AMD; anti-VEGF; IL-1α; IL-1β; polymorphism
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
2. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng C-Y, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. The Lancet Global Health. 2014 Feb;2(2):e106–e116. doi:10.1016/s2214-109x(13)70145-1
3. Jiang B, Jiang C, Li J, Lu P. Trends and disparities in disease burden of age-related macular degeneration from 1990 to 2019: Results from the global burden of disease study 2019. Frontiers in Public Health. 2023 Apr 17;11. doi:10.3389/fpubh.2023.1138428
4. Almony A. Disease burden of neovascular age-related macular degeneration and diabetic macular edema. The American Journal of Managed Care. 2023 Jun 1;29(Suppl 6). doi:10.37765/ajmc.2023.89387
5. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews. 2019 Mar 4;2019(3). doi:10.1002/14651858.cd005139.pub4
6. Almony A, Keyloun KR, Shah-Manek B, Multani JK, McGuiness CB, Chen C-C, et al. Clinical and economic burden of neovascular age-related macular degeneration by disease status: A US claims-based analysis. Journal of Managed Care and Specialty Pharmacy. 2021 Sept;27(9):1260–72. doi:10.18553/jmcp.2021.27.9.1260
7. Nassar K, Grisanti S, Elfar E, Lüke J, Lüke M, Grisanti S. Serum cytokines as biomarkers for age-related macular degeneration. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2014 Jul 24;253(5):699–704. doi:10.1007/s00417-014-2738-8
8. Wooff Y, Man SM, Aggio-Bruce R, Natoli R, Fernando N. IL-1 family members mediate cell death, inflammation and angiogenesis in retinal degenerative diseases. Frontiers in Immunology. 2019 Jul 16;10. doi:10.3389/fimmu.2019.01618
9. Cai H, Sun H-J, Wang Y-H, Zhang Z. Relationships of common polymorphisms in il-6, IL-1A, and IL-1B genes with susceptibility to osteoarthritis: A meta-analysis. Clinical Rheumatology. 2014 Jun 21;34(8):1443–53. doi:10.1007/s10067-014-2708-x
10. Harati-Sadegh M, Sargazi S, Khorasani M, Ansari-Moghaddam A, Mirinejad S, Sheervalilou R, et al. IL1A and IL1B gene polymorphisms and keratoconus susceptibility: Evidence from an updated meta-analysis. Ophthalmic Genetics. 2021 May 12;42(5):503–13. doi:10.1080/13816810.2021.1925926
11. Ankem MK, Yanamandra K, Napper D, Boggs P, Mills G, Bocchini J, et al. VEGF and interleukin gene haplotypes and prostate cancer among Caucasians. Journal of the American College of Surgeons. 2007 Sept;205(3). doi:10.1016/j.jamcollsurg.2007.06.089
12. Mohammed TF, Qadir FA. Detection of il-1β, VEGF and IL-4 with their novel genetic variations in breast cancer patients. Saudi Journal of Biological Sciences. 2023 Feb;30(2):103544. doi:10.1016/j.sjbs.2022.103544
13. Oliveira MB, de Vasconcellos JP, Ananina G, Costa VP, de Melo MB. Association between il1a and il1b polymorphisms and primary open angle glaucoma in a Brazilian population. Experimental Biology and Medicine. 2018 Sept;243(13):1083–91. doi:10.1177/1535370218809709
14. Nassar K, Elfar E, Lüke J, Lüke M, Grisanti S. Inflammatory Cytokines in Age Related Macular Degeneration (AMD): Relationships to Disease Activity. Investigative Ophthalmology & Visual Science. 2013 Jun;54(15):141.
15. Tsai Y-Y, Lin J-M, Wan L, Lin H-J, Tsai Y, Lee C-C, et al. Interleukin gene polymorphisms in age-related macular degeneration. Investigative Opthalmology & Visual Science. 2008 Feb 1;49(2):693. doi:10.1167/iovs.07-0125
16. Makita LS, Muniz BC, da Silva AB, Bajano FF, Hirata FE, do Amaral M, et al. Interleukin-1β-31 (rs1143627) genetic variant and the risk of age-related macular degeneration in the Brazilian population. Ophthalmic Genetics. 2021 Jun 16;42(5):533–8. doi:10.1080/13816810.2021.1929337
17. Wong JH, Ma JY, Jobling AI, Brandli A, Greferath U, Fletcher EL, et al. Exploring the pathogenesis of age-related macular degeneration: A review of the interplay between retinal pigment epithelium dysfunction and the innate immune system. Frontiers in Neuroscience. 2022 Nov 3;16. doi:10.3389/fnins.2022.1009599
18. Tan W, Zou J, Yoshida S, Jiang B, Zhou Y. The role of inflammation in age-related macular degeneration. International Journal of Biological Sciences. 2020;16(15):2989–3001. doi:10.7150/ijbs.49890